iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $48.49 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-04-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-04-14
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $0.00.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-06-30 was $2.10K.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-03-31 was $46.39K, a 86.22% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $48.49K, a 77.61% decline from fiscal 2022.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $216.63K, a 42.88% decline from fiscal 2021.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $379.28K.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $0.00 derived: sum of 2 quarters · filed 2025-04-14 | $2.10K derived: sum of 3 quarters · filed 2025-04-14 | $48.49K 10-K · filed 2025-04-14 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.10K derived: sum of 2 quarters · filed 2024-11-07 | $48.49K 10-Q · filed 2024-11-07 | $212.63K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $48.49K 10-Q · filed 2024-08-06 | $212.63K derived: sum of 3 quarters · filed 2024-08-06 | $174.10K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $46.39K 10-Q · filed 2024-05-07 | $210.52K derived: sum of 2 quarters · filed 2024-05-07 | $172.00K derived: sum of 3 quarters · filed 2024-05-07 | -$73.62K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $164.13K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $125.61K derived: sum of 2 quarters · filed 2024-03-13 | -$120.01K derived: sum of 3 quarters · filed 2024-03-13 | $216.63K 10-K · filed 2024-03-13 |
| 2022-09-30 | -$38.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$284.14K derived: sum of 2 quarters · filed 2023-11-02 | $52.49K 10-Q · filed 2023-11-02 | $217.96K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$245.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $91.02K 10-Q · filed 2023-08-02 | $256.48K derived: sum of 3 quarters · filed 2023-08-02 | $279.50K derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $336.63K 10-Q · filed 2023-05-04 | $502.10K derived: sum of 2 quarters · filed 2023-05-04 | $525.11K derived: sum of 3 quarters · filed 2023-05-04 | $770.56K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $165.46K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $188.48K derived: sum of 2 quarters · filed 2023-03-30 | $433.93K derived: sum of 3 quarters · filed 2023-03-30 | $379.28K 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $23.02K 10-Q · filed 2021-11-04 | $268.47K derived: sum of 2 quarters · filed 2021-11-04 | $213.81K 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $245.45K 10-Q · filed 2021-08-10 | $245.45K 10-Q · filed 2021-08-10 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |